These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

138 related items for PubMed ID: 8714754

  • 21. [New pharmacologic strategies for the treatment of Parkinson disease].
    Tolosa E, Molinuevo JL, Valldeoriola F, Pastor P.
    Neurologia; 1999 May; 14 Suppl 1():46-53. PubMed ID: 10377729
    [Abstract] [Full Text] [Related]

  • 22. Diversity of dopamine receptors: new molecular and pharmacological developments.
    Hartman DS, Lanau F.
    Pol J Pharmacol; 1997 Aug; 49(4):191-9. PubMed ID: 9437762
    [Abstract] [Full Text] [Related]

  • 23. Clinical pharmacology of levodopa-induced dyskinesia in parkinsonian patients.
    Rascol O, Brefel-Courbon C, Descombes S, Montastruc JL.
    Adv Neurol; 1999 Aug; 80():485-90. PubMed ID: 10410760
    [No Abstract] [Full Text] [Related]

  • 24. Association study between dopamine D1, D2, D3, and D4 receptor genes and schizophrenia defined by several diagnostic systems.
    Dollfus S, Campion D, Vasse T, Preterre P, Laurent C, d'Amato T, Thibaut F, Mallet J, Petit M.
    Biol Psychiatry; 1996 Sep 01; 40(5):419-21. PubMed ID: 8874845
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Striatal dopamine D1 and D2 receptor balance in twins at increased genetic risk for schizophrenia.
    Hirvonen J, van Erp TG, Huttunen J, Någren K, Huttunen M, Aalto S, Lönnqvist J, Kaprio J, Cannon TD, Hietala J.
    Psychiatry Res; 2006 Jan 30; 146(1):13-20. PubMed ID: 16361088
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. [Updates in practical neurology--I. The principles of modern levodopa therapy in Parkinson's disease].
    Klivényi P, Vécsei L.
    Ideggyogy Sz; 2007 Jan 20; 60(1-2):61-4. PubMed ID: 17432097
    [Abstract] [Full Text] [Related]

  • 36. Ropinirole in the symptomatic treatment of Parkinson's disease.
    Brooks DJ, Torjanski N, Burn DJ.
    J Neural Transm Suppl; 1995 Jan 20; 45():231-8. PubMed ID: 8748630
    [Abstract] [Full Text] [Related]

  • 37. Dopaminergic modulation of cognitive function-implications for L-DOPA treatment in Parkinson's disease.
    Cools R.
    Neurosci Biobehav Rev; 2006 Jan 20; 30(1):1-23. PubMed ID: 15935475
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.